Arvinas, Inc. (NASDAQ: ARVN)

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics using its proprietary PROteolysis TArgeting Chimera or PROTAC platform to degrade disease causing proteins. The company designs small molecule compounds that recruit an E3 ubiquitin ligase to a target protein, forming a ternary complex that leads to ubiquitination and proteasomal degradation. This approach differs from traditional inhibition because it removes the protein entirely rather than blocking its activity. Arvinas, Inc. aims to treat serious illnesses such as cancer and neurodegenerative disorders by eliminating pathogenic proteins that drive disease. Its pipeline includes multiple candidates targeting proteins like estrogen receptor, KRAS G12D, BCL6, LRRK2 and the androgen receptor. The company leverages its drug discovery engine to create small molecule degraders that can engage the cell's natural ubiquitin proteasome system and potentially offer oral dosing and broad tissue distribution.

Arvinas, Inc. generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical firms. In July 2021 the company received an upfront payment of $650 million from Pfizer for the co development and co commercialization of vepdegestrant, with potential milestone payments reaching up to $1.4 billion. In April 2024 Arvinas, Inc. entered into a transaction with Novartis that included an upfront payment of $150 million and the right to receive up to $1.01 billion in milestones, of which $20 million was recognized during 2025. Additionally the company earned $28 million from an earlier research collaboration with Pfizer and is eligible for further milestone and royalty payments under various agreements. As of the filing date Arvinas, Inc. has not yet commercialized any product, so its revenue consists of these upfront, milestone and potential royalty payments. The company also retains rights to receive tiered royalties on net sales of licensed products should any of its candidates reach the market.

Arvinas, Inc. occupies a pioneering position in the emerging field of targeted protein degradation, a modality that seeks to eliminate disease causing proteins through the cell's ubiquitin system. The company faces competition from other biotech firms pursuing similar approaches, including C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics and others that develop degraders or molecular glues. Arvinas, Inc. differentiates itself with a proprietary PROTAC discovery engine that enables the design of degraders capable of targeting traditionally undruggable proteins such as transcription factors and scaffolding molecules. Its platform also offers potential advantages like oral bioavailability, catalytic activity and the ability to spare healthy proteins while degrading disease associated variants. Notably Arvinas, Inc. was the first to submit a new drug application for a PROTAC based therapy, underscoring its innovative edge in the field.

Arvinas, Inc. ultimately serves patients suffering from oncology and neurology conditions who may benefit from its investigational therapies. In oncology the company focuses on patients with estrogen receptor positive HER2 negative breast cancer, non small cell lung cancer, colorectal cancer and pancreatic cancer harboring specific mutations such as KRAS G12D. In neurology the company targets individuals with Parkinson's disease, progressive supranuclear palsy and other neurodegenerative disorders linked to proteins like LRRK2. In hematology Arvinas, Inc. develops agents for relapsed or refractory non Hodgkin lymphoma by targeting the BCL6 transcription factor. Additionally the company works on treatments for spinal bulbar muscular atrophy by addressing the mutant androgen receptor in skeletal muscle. In the near term the company's customers are its collaborative partners, namely Pfizer with whom it co develops vepdegestrant, Novartis which holds the rights to luxdegalutamide and Genentech with which it has explored multiple target programs. These partnerships provide the near term revenue stream while the long term goal is to deliver medicines directly to patients and healthcare providers.